United States Patent 7,795,312: Claim Scope, Lubiprostone Coverage, and Patent Landscape

US Patent 7,795,312 is a method-of-treatment patent covering the use of difluorinated prostaglandin E1 derivatives, including lubiprostone-related compounds, for irritable bowel syndrome and abdominal discomfort associated with irritable bowel syndrome. The patent does not claim a composition, dosage form, manufacturing process, or drug product. Its commercial importance depends on whether a product is administered with an IBS indication or for an IBS-associated symptom within the claimed dosage and compound scope.

The patent issued on September 14, 2010. Its claims are directed principally to:

Treatment of irritable bowel syndrome.
Treatment of abdominal discomfort associated with irritable bowel syndrome.
13,14-dihydro-15-keto-16,16-difluoro prostaglandin E1 and its 18-methyl derivative.
Salts, ethers, esters, amides, and pharmaceutically acceptable versions of those compounds.
Systemic administration one to four times daily or continuous administration.
Daily doses of 0.01 to 100 micrograms per kilogram, with a narrower preferred range of 0.1 to 10 micrograms per kilogram.

What drug and active ingredient does US 7,795,312 cover?

The patent covers prostaglandin derivatives structurally related to lubiprostone. Lubiprostone is a bicyclic prostaglandin derivative used in Amitiza capsules. The compound is generally identified chemically as 13,14-dihydro-15-keto-16,16-difluoroprostaglandin E1, with the marketed active ingredient corresponding to the relevant substituted derivative described in the patent and product labeling.

Lubiprostone is approved in the United States for:

Indication	Typical marketed strength
Chronic idiopathic constipation in adults	24 mcg twice daily
Irritable bowel syndrome with constipation in adult women	8 mcg twice daily
Opioid-induced constipation in adults with chronic non-cancer pain	24 mcg twice daily

The 8 mcg IBS-C indication is the principal regulatory use relevant to the patent. The patent claims are broader in some respects because they recite IBS generally and do not limit treatment to constipation-predominant IBS.

How many independent claim concepts does the patent contain?

The 22 claims contain four principal claim groups.

Claims	Protected subject	Compound scope	Symptom scope
1-6	IBS treatment	18-methyl difluoro prostaglandin E1 derivative	IBS generally
7-12	IBS treatment	Non-18-methyl difluoro prostaglandin E1 derivative	IBS generally
13-17	IBS-associated abdominal discomfort	18-methyl derivative	Abdominal discomfort
18-22	IBS-associated abdominal discomfort	Non-18-methyl derivative	Abdominal discomfort

Within each group, the claims add:

Pharmaceutically acceptable salts, esters, ethers, or amides.
Systemic administration.
One to four administrations per day or continuous administration.
A dose of 0.01 to 100 micrograms per kilogram per day.
A narrower dose of 0.1 to 10 micrograms per kilogram per day.

Claims 1, 7, 13, and 18 are the key independent claims. The remaining claims narrow those independent claims by adding pharmaceutical form, dosing frequency, route, or dose.

What is the scope of independent claim 1?

Claim 1 covers a method of treating IBS in a mammalian subject by administering an effective amount of the 18-methyl difluoro prostaglandin E1 derivative, or a salt, ether, ester, or amide.

The claim has five material limitations:

A method of treatment.
A mammalian subject.
The subject has IBS.
The administered active is the specified prostaglandin derivative or a listed derivative form.
The amount administered is effective for treatment.

Claim 1 does not require:

A specified route of administration.
A specified dosage.
A specified formulation.
A particular IBS subtype.
A particular patient sex.
A particular degree of symptom improvement.
A particular dosing frequency.

That makes claim 1 materially broader than claims 3 through 6. A product could fall within claim 1 even if the dosage is outside the narrower 0.01 to 100 microgram-per-kilogram range, provided the treatment uses the recited active compound and is otherwise within the claim.

What is the scope of independent claims 7, 13, and 18?

Claim 7 is similar to claim 1 but covers the non-18-methyl version of 13,14-dihydro-15-keto-16,16-difluoroprostaglandin E1.

Claims 13 and 18 shift the therapeutic endpoint from IBS generally to abdominal discomfort associated with IBS.

This distinction matters because a product label or prescribing practice directed to abdominal discomfort could create infringement exposure even if the label does not expressly use the broader phrase “treating irritable bowel syndrome.” Claims 13 and 18 require the abdominal discomfort to be associated with IBS, so use for nonspecific abdominal pain outside an IBS diagnosis would not necessarily satisfy the claim language.

The two compound branches are important:

The 18-methyl branch covers the substituted derivative.
The non-18-methyl branch covers the corresponding unsubstituted derivative.
Both branches extend to certain salts, ethers, esters, and amides.
The claims do not expressly require lubiprostone to be administered as the free acid.

Do the claims cover lubiprostone formulations?

The patent claims treatment methods, not formulations.

A capsule, tablet, liquid, softgel, or other dosage form is relevant only as the delivery vehicle for the claimed method. The patent does not independently claim:

A capsule containing lubiprostone.
A specific concentration.
A particular excipient.
A crystalline form.
A polymorph.
An enteric coating.
A controlled-release profile.
A manufacturing process.

A generic manufacturer would therefore need to analyze separate composition, formulation, and process patents, if any, in addition to US 7,795,312. Avoiding a formulation claim would not necessarily avoid a method-of-use claim if the generic label directs use for IBS or IBS-associated abdominal discomfort.

What dosage and administration methods are protected?

Claims 3 through 6 and 9 through 12 recite systemic administration one to four times daily or continuous administration. They specify:

Broad dose: 0.01 to 100 micrograms per kilogram per day.
Narrow dose: 0.1 to 10 micrograms per kilogram per day.

Claims 15 through 17 and 20 through 22 apply comparable dose limitations to treatment of abdominal discomfort.

Amitiza’s labeled IBS-C regimen is 8 micrograms twice daily. For a 60-kilogram adult, that equals approximately 0.267 micrograms per kilogram per day. That dose falls within the patent’s narrower 0.1 to 10 microgram-per-kilogram range.

The commercial dose therefore aligns with the narrower dependent claims, assuming the active ingredient and treatment indication satisfy the relevant compound and disease limitations.

How strong is the patent estate for IBS treatment?

US 7,795,312 has meaningful method-of-use coverage but a narrower enforcement profile than a composition-of-matter patent.

Patent characteristic	Assessment
Claim category	Method of treatment
Product claim	None
Composition claim	None
Manufacturing claim	None
IBS indication	Directly covered
Abdominal discomfort associated with IBS	Directly covered
Dose range	Broad, with narrower dependent range
Route	Independent claims are not expressly limited to systemic administration
Salt and derivative coverage	Expressly included
Generic label risk	Material for an IBS-directed label
Off-label use risk	More difficult to establish without evidence of induced use
Formulation independence	Yes, but separate formulation patents may apply

The patent is stronger against a generic company seeking the IBS indication on its label than against a manufacturer selling the same active ingredient with a label limited to a non-IBS indication.

When does US 7,795,312 lose exclusivity?

The statutory patent term is generally 20 years from the earliest effective nonprovisional filing date under the Uruguay Round Agreements Act framework. The patent issued in 2010, but the issue date does not determine expiration.

Public Orange Book and patent-record sources have associated the patent with the later-stage Amitiza exclusivity position and an expiration date in the 2027 period. The exact enforceable term depends on the patent’s effective filing chain, any terminal disclaimer, patent-term adjustment, and any applicable patent-term extension or pediatric exclusivity.

Exclusivity element	Relevance
Patent term	Controls ordinary patent exclusivity
Patent-term adjustment	May extend the nominal term for USPTO delay
Patent-term extension	Requires an eligible regulatory-review basis
Pediatric exclusivity	Can add six months to listed exclusivity in qualifying circumstances
FDA drug exclusivity	Separate from patent term
Orange Book listing	Supports notice and Paragraph IV litigation procedures

The FDA Orange Book should be treated as the operative source for listed drug patents and expiration dates, while USPTO Patent Center and the patent file history control prosecution, term-adjustment, and disclaimer questions. [1][2]

What is the Orange Book status of Amitiza and US 7,795,312?

Amitiza is the reference drug associated with lubiprostone. Orange Book analysis should distinguish between:

Patents listed for the drug product.
Patents directed to specific approved methods of use.
Patent claims that correspond to an approved indication.
Patent claims that may not cover every approved strength or indication.

A method-of-use patent can be listed with an indication code rather than as a broad product patent. For an ANDA applicant, the listing creates a certification issue if the applicant seeks approval for the corresponding indication.

A generic applicant may attempt a “section viii” statement and omit the patented IBS indication. That strategy reduces direct method-of-use exposure but does not eliminate risk if the labeling, promotional materials, or distribution practices encourage the patented use.

Which companies have challenged the Amitiza patent estate?

Amitiza has been subject to generic competition and Paragraph IV activity involving generic-drug manufacturers. Public litigation involving Sucampo and generic applicants has focused on the validity, enforceability, and infringement of patents associated with lubiprostone and Amitiza.

The principal legal issues in this class of dispute include:

Obviousness of using prostaglandin derivatives for IBS.
Written description and enablement of broad derivative and salt language.
Anticipation by earlier prostaglandin and gastrointestinal-treatment disclosures.
Whether an ANDA label induces infringement.
Whether a generic label properly carves out the patented IBS use.
The effect of settlement agreements on launch timing.

Paragraph IV litigation is especially important for US 7,795,312 because the patent is a use patent rather than a product patent. The litigation question is not only whether the generic contains lubiprostone. It is whether the proposed labeling and foreseeable use direct treatment of IBS or IBS-associated abdominal discomfort within the claims.

What litigation and settlement risks apply?

A patent owner asserting this patent would typically rely on 35 U.S.C. §271(e)(2) against an ANDA filing and could assert induced infringement under 35 U.S.C. §271(b) if the generic label encourages the patented use. [3]

A generic applicant would likely pursue one or more of the following positions:

The claims are invalid as obvious over earlier prostaglandin and gastrointestinal literature.
The claims lack adequate written description for the full range of salts, ethers, esters, and amides.
The proposed label omits the IBS indication.
The product is not administered in a claimed manner.
The relevant compound is outside the claimed structural definition.
The patent is expired or unenforceable.
The patent is not infringed by the proposed commercial conduct.

Settlement agreements may permit an authorized generic, delayed entry, or a launch before the nominal patent-expiration date. The existence of a settlement does not establish patent validity. The agreement terms, court docket, and FTC reporting materials control the commercial interpretation. [4]

What geographic coverage does the patent provide?

US 7,795,312 provides rights only in the United States. It does not directly block:

Manufacture solely for non-US markets.
Sale in Canada, Europe, Japan, or other jurisdictions.
Use outside the United States.
Foreign regulatory approval.

Parallel foreign patents may have been filed from the same priority family, but each jurisdiction requires separate analysis of:

Grant status.
Claim scope.
Patent-term calculation.
Supplementary protection certificates.
Validity proceedings.
National settlement terms.
Regulatory exclusivity.

US market entry therefore cannot be inferred from the status of corresponding European, Canadian, or Japanese rights.

What generic launch scenarios exist?

Launch scenario	Risk under US 7,795,312
Generic seeks IBS-C indication	High method-of-use risk if the patent remains enforceable
Generic omits IBS indication	Lower direct infringement risk, but labeling must be carefully carved out
Generic seeks chronic idiopathic constipation only	Potentially lower risk under this patent, subject to label and other patents
Generic markets off-label IBS use	Induced-infringement risk depends on evidence of encouragement
Generic uses a different salt or derivative	Requires structural claim analysis; listed derivative forms are expressly covered
Generic changes formulation only	Does not avoid the method claims if the active and use remain within scope
Generic launches after patent expiration	No ordinary infringement risk from the expired patent

What licensing and commercial transactions affect the patent?

Lubiprostone was developed through a collaboration involving Sucampo and R-Tech Ueno, with Takeda later holding significant US commercial rights for Amitiza. Commercial rights and patent ownership are separate questions. A license can authorize commercial sales without transferring patent title, while a corporate acquisition can transfer both operating rights and patent interests.

Later changes in Amitiza commercialization, including transactions involving Takeda and successor commercial partners, should be analyzed against the specific patent assignment and license records rather than the product label alone. The relevant records are USPTO assignment documents, SEC filings, FDA listing information, and transaction announcements. [5][6]

What are the principal invalidity vulnerabilities?

The principal vulnerabilities are structural and legal rather than manufacturing-related.

Obviousness

The patent claims use a known prostaglandin-derived chemical class for a gastrointestinal disorder. An obviousness challenge would examine whether the prior art provided:

A motivation to use the compound for IBS.
A reasonable expectation of success.
Evidence that the compound had a useful IBS effect.
A reason to select the claimed dose and administration schedule.

Written description and enablement

The claims cover salts, ethers, esters, and amides, while the commercial product may use a narrower active form. A challenger could argue that the specification does not adequately describe or enable every claimed derivative across the full breadth of the claims.

Claim construction

The patent uses overlapping and repetitive claim language. The phrases “effective amount,” “treating IBS,” “abdominal discomfort associated with IBS,” and the compound names would be central to any construction dispute.

Infringement proof

For method claims, the patent owner must link the accused product’s labeling or conduct to the claimed treatment. Chemical identity alone does not establish infringement of a treatment method.

Key Takeaways

US 7,795,312 is an IBS and IBS-associated abdominal-discomfort method patent.
It covers difluorinated prostaglandin E1 derivatives, including compound forms related to lubiprostone.
Claims 1, 7, 13, and 18 provide the main independent claim coverage.
The patent does not claim a capsule, formulation, polymorph, manufacturing process, or product composition.
Amitiza’s 8 mcg twice-daily IBS-C regimen falls within the dependent claims’ narrower dosing range for a typical adult.
The strongest infringement theory concerns a generic label that expressly seeks or encourages the IBS indication.
A non-IBS label may reduce risk but must be assessed against induced-use evidence and other listed patents.
The patent’s commercial value depends on its effective expiration date, Orange Book status, any terminal disclaimer, and the outcome of Paragraph IV litigation or settlements.
Separate composition, formulation, process, foreign, and regulatory exclusivities must be analyzed alongside this patent.

FAQs About US Patent 7,795,312

Does US 7,795,312 claim lubiprostone itself?

No. The patent claims methods of administering specified prostaglandin derivatives for IBS or IBS-associated abdominal discomfort. It does not contain a standalone product claim to lubiprostone.

Can a generic manufacturer avoid the patent by using a different capsule formulation?

Not necessarily. A different capsule or excipient profile may avoid a separate formulation patent, but it does not avoid US 7,795,312 if the generic administers a covered compound for a claimed IBS use.

Does a chronic idiopathic constipation label necessarily infringe this patent?

No. A constipation-only label may not satisfy the IBS limitations. The analysis still depends on the compound, label language, promotional conduct, and other patents covering lubiprostone.

Does a salt or ester of the active compound escape the patent?

Not if it falls within the claimed salt, ether, ester, or amide language and is used for a claimed indication. Chemical identity and claim construction would determine the result.

Is the patent still relevant after generic lubiprostone approval?

Yes. FDA approval and patent expiration are separate events. A generic may receive approval while carving out a patented indication, or may face launch restrictions based on litigation, settlement, or remaining enforceable claims.

References

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
United States Patent and Trademark Office. (2010). U.S. Patent No. 7,795,312, methods for treating irritable bowel syndrome. https://patents.google.com/patent/US7795312B2/en
35 U.S.C. §§ 271(b), 271(e)(2) (2024).
Federal Trade Commission. (2024). Agreements filed under the Medicare Prescription Drug, Improvement, and Modernization Act. https://www.ftc.gov
Takeda Pharmaceutical Company Limited. (2018). Takeda completes acquisition of Shire plc. https://www.takeda.com
U.S. Food and Drug Administration. (2024). Amitiza prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	042670	⤷ Start Trial
Argentina	106393	⤷ Start Trial
Australia	2003292556	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,795,312

Summary for Patent: 7,795,312